The company's innovative approach uses DNA sequencing systems to develop next-generation antimicrobials that can eradicate resistant pathogens or virulent bacteria within the human microbiome. Pharmaceutical companies can use these pathogen-resistant antimicrobials to create medicines, making Eligo Bioscience a biotechnology company that pioneers a new class of biotherapeutics for microbiome precision-editing.